...
首页> 外文期刊>The Australian and New Zealand journal of psychiatry >Prevalence, correlates and comorbidity of DSM-IV Cannabis Use and Cannabis Use Disorders in Australia.
【24h】

Prevalence, correlates and comorbidity of DSM-IV Cannabis Use and Cannabis Use Disorders in Australia.

机译:澳大利亚DSM-IV大麻使用和大麻使用障碍的患病率,相关性和合并症。

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To report nationally representative findings on the prevalence, correlates, psychiatric comorbidity and treatment of DSM-IV Cannabis Use and Cannabis Use Disorders in Australia. Method: The 2007 National Survey of Mental Health and Wellbeing was a nationally representative household survey of 8841 Australians (16-85 years) that assessed symptoms of the most prevalent DSM-IV mental disorders. Results: Prevalence of lifetime and 12-month cannabis use was 18% and 6%; prevalence of lifetime and 12-month cannabis use disorder was 6% and 1%. The conditional prevalence (proportion of ever users who met criteria for a disorder) of lifetime and 12-month cannabis use disorder was 32.2% and 14.3%. Current cannabis use disorders were more common in males (OR 2.0) and younger users (OR 4.6). Strong associations were observed between current cannabis use disorders and alcohol use disorders (OR 3.6) and current affective disorders (OR 3.0). Only 36.2% of those with current cannabis use disorders sought any treatment. Conclusions: The prevalence of cannabis use disorders in the Australian population is comparable with that in the USA. Current cannabis use disorders are highly concentrated in young Australians who have high levels of comorbidity. The low rates of treatment seeking warrant attention in treatment and prevention strategies.
机译:目的:举报对澳大利亚普遍存在,相关性,精神病毒使用者和大麻使用疾病的患病率,相关性,精神病合并和治疗的国家代表性调查结果。方法:2007年国家心理健康和福祉调查是一项全国代表性的家庭调查,澳大利亚人澳大利亚人(16-85岁)评估了最普遍的DSM-IV精神障碍的症状。结果:寿命患病率和12个月大麻用量为18%和6%;寿命和12个月大麻使用障碍的患病率为6%和1%。条件患病率(符合疾病标准的用户的比例)终身和12个月大麻使用障碍的持续障碍为32.2%和14.3%。目前的大麻使用障碍在男性(或2.0)和年轻用户(或4.6)中更常见。在当前大麻使用障碍和酒精使用障碍(或3.6)和当前情感障碍(或3.0)之间观察到强烈的关联。只有36.2%的那些有当前大麻使用障碍的人寻求任何治疗。结论:澳大利亚人口大麻使用障碍的患病率与美国相当。目前的大麻使用障碍高度集中在具有高水平合并症的年轻澳大利亚人中。寻求治疗和预防策略的持证注意力的低率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号